Abstract
Pancreatic cancer is one of the most resistant cancers to conventional treatment modalities and is generally in the locally advanced or metastatic stage at the time of initial diagnosis. Approximately only 20% of patients are diagnosed as potentially resectable but 5-year survival rate is no more than 20-25% even in these resectable ones. Realizing the poor prognosis with a single-modality approach, several studies that used the combination of chemotherapy and radiotherapy with surgery are performed in order to improve local control and survival. This review evaluates the existing data and future aspects about the combined modality treatment in locally advanced pancreatic cancer regarding both the efficiency and toxicity of these combinations and novel agents.
Keywords: pancreaticoduodenectomy, chemotherapy, intraoperative radiotherapy (IORT), adenocarcinoma, neoadjuvant therapy, streptozocin, computed tomographic (CT), gemcitabine
Current Cancer Therapy Reviews
Title: Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer
Volume: 1 Issue: 3
Author(s): Gorkem Aksu, Binnaz Sarper, Cuneyt Ulutin and Hakan Bakkal
Affiliation:
Keywords: pancreaticoduodenectomy, chemotherapy, intraoperative radiotherapy (IORT), adenocarcinoma, neoadjuvant therapy, streptozocin, computed tomographic (CT), gemcitabine
Abstract: Pancreatic cancer is one of the most resistant cancers to conventional treatment modalities and is generally in the locally advanced or metastatic stage at the time of initial diagnosis. Approximately only 20% of patients are diagnosed as potentially resectable but 5-year survival rate is no more than 20-25% even in these resectable ones. Realizing the poor prognosis with a single-modality approach, several studies that used the combination of chemotherapy and radiotherapy with surgery are performed in order to improve local control and survival. This review evaluates the existing data and future aspects about the combined modality treatment in locally advanced pancreatic cancer regarding both the efficiency and toxicity of these combinations and novel agents.
Export Options
About this article
Cite this article as:
Aksu Gorkem, Sarper Binnaz, Ulutin Cuneyt and Bakkal Hakan, Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574199
DOI https://dx.doi.org/10.2174/157339405774574199 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets The Role of Stromal Components in Pancreatic Cancer Progression
Anti-Cancer Agents in Medicinal Chemistry Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer
Current Pharmaceutical Design Vascular and Metabolic Actions of the Green Tea Polyphenol Epigallocatechin Gallate
Current Medicinal Chemistry Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Current Topics in Medicinal Chemistry Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo
Current Cancer Drug Targets Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry